Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation

NCT: NCT04950894 · COMPLETED

NCT IDNCT04950894
StatusCOMPLETED
Start Date2022-02-24
Completion2025-04-23
SponsorLivaNova (INDUSTRY)
First posted
Last updated

Brief Summary

Multi-center, open-label, prospective, randomized clinical trial of the aura6000(R) System for the reduction of apnea and hypopneas in adult patients with moderate to severe obstructive sleep apnea who have failed or are unwilling to use positive airway pressure treatment.

Frequently Asked Questions

What is Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation?

Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation is a clinical trial registered under NCT04950894. Current status: COMPLETED.

What is the status of NCT04950894?

The current status of NCT04950894 (Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation) is: COMPLETED.

When did Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation start?

Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation started on 2022-02-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.